Peter G. Kremsner

ORCID: 0000-0002-3926-4113
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Malaria Research and Control
  • Mosquito-borne diseases and control
  • Parasites and Host Interactions
  • Complement system in diseases
  • SARS-CoV-2 and COVID-19 Research
  • Hepatitis B Virus Studies
  • Global Maternal and Child Health
  • Immune Cell Function and Interaction
  • Trypanosoma species research and implications
  • Parasite Biology and Host Interactions
  • Research on Leishmaniasis Studies
  • Computational Drug Discovery Methods
  • Hemoglobinopathies and Related Disorders
  • Hepatitis C virus research
  • Drug-Induced Hepatotoxicity and Protection
  • Child Nutrition and Water Access
  • vaccines and immunoinformatics approaches
  • Viral Infections and Outbreaks Research
  • Viral gastroenteritis research and epidemiology
  • HIV Research and Treatment
  • Viral Infections and Vectors
  • COVID-19 Clinical Research Studies
  • Tuberculosis Research and Epidemiology
  • Vector-borne infectious diseases
  • Antimicrobial Resistance in Staphylococcus

University of Tübingen
2016-2025

German Center for Infection Research
2016-2025

Centre de Recherche Médicales de Lambaréné
2016-2025

Universitätsklinikum Tübingen
2015-2024

University Children's Hospital Tübingen
2011-2024

German Institute for Disaster Medicine
2007-2023

Bernstein Center for Computational Neuroscience Tübingen
2023

Naval Medical Research Command
2023

Institut Africain d'Informatique
2021-2022

Vietnamese - German Center of Excellence in Medical Research
2016-2021

Selidji Todagbé Agnandji Bertrand Lell Solange Soulanoudjingar José Francisco Fernandes Béatrice Peggy Abossolo and 95 more Cornelia Conzelmann Barbara Gaelle Nfono Ondo Methogo Yannick Doucka Arnaud Flamen Benjamin Mordmüller Saadou Issifou Peter G. Kremsner Jahit Sacarlal Pedro Aíde Miguel Lanaspa John J. Aponte Arlindo Nhamuave Diana Quelhas Quique Bassat Sofia Mandjate Eusébio Macete Pedro L. Alonso Salim Abdulla Nahya Salim Omar Juma Mwanajaa Shomari Kafuruki Shubis Francisca Machera Ali Hamad Rose Minja Ali Mtoro Alma Sykes Saumu Ahmed Alwisa Urassa Ali Mohammed Ali Grace Mwangoka Marcel Tanner Halidou Tinto Umberto D’Alessandro Hermann Sorgho Innocent Valéa Marc Christian Tahita William Kaboré Sayouba Ouédraogo Yara Sandrine Robert Tinga Guiguemdé Jean‐Bosco Ouédraogo Mary J. Hamel Simon Kariuki Chris Odero Martina Oneko Kephas Otieno Norbert Awino Jackton Omoto John Williamson Vincent Muturi‐Kioi Kayla F. Laserson Laurence Slutsker Walter Otieno Lucas Otieno Otsyula Nekoye Stacey Gondi Allan Otieno Bernhards Ogutu Ruth Wasuna Victorine Owira D. Stephen Charnock‐Jones Agnes Akoth Onyango Patricia Njuguna Roma Chilengi Pauline Akoo Christine Kerubo Jesse Gitaka Charity Maingi Trudie Lang Ally Olotu Benjamin Tsofa Philip Bejon Norbert Peshu Kevin Marsh Seth Owusu‐Agyei Kwaku Poku Asante Kingsley Osei-Kwakye Owusu Boahen Samuel Ayamba Kingsley Kayan Ruth Owusu-Ofori David Dosoo Isaac Asante George Adjei Daniel Chandramohan Brian Greenwood John Lusingu Samwel Gesase Anangisye Malabeja Omari Abdul Msemo Kilavo Hassan Coline Mahende Edwin Liheluka Martha Lemnge

An ongoing phase 3 study of the efficacy, safety, and immunogenicity candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.From March 2009 through January 2011, we enrolled 15,460 children two age categories--6 to 12 weeks 5 17 months age--for vaccination with either or a non-malaria comparator vaccine. The primary end point analysis was efficacy against clinical during after first 6000 at enrollment who received all three doses according protocol. After 250 had...

10.1056/nejmoa1102287 article EN New England Journal of Medicine 2011-10-18
Selidji Todagbé Agnandji Bertrand Lell José Francisco Fernandes Béatrice Peggy Abossolo Barbara Gaelle Nfono Ondo Methogo and 95 more Anita L. Kabwende Ayôla Akim Adégnika Benjamin Mordmüller Saadou Issifou Peter G. Kremsner Jahit Sacarlal Pedro Aíde Miguel Lanaspa John J Aponte Sónia Machevo Sozinho Acácio Helder Bulo Betuel Sigaúque Eusébio Macete Pedro L. Alonso Salim Abdulla Nahya Salim Rose Minja Maxmillian Mpina Saumu Ahmed Ali Mohammed Ali Ali Mtoro Ali Hamad Paul Mutani Marcel Tanner Halidou Tinto Umberto D’Alessandro Hermann Sorgho Innocent Valéa Biébo Bihoun Issa Guiraud Bérenger Y. L. Kaboré Olivier Sombié Robert Tinga Guiguemdé Jean‐Bosco Ouédraogo Mary J. Hamel Simon Kariuki Martina Oneko Chris Odero Kephas Otieno Norbert Awino Meredith McMorrow Vincent Muturi‐Kioi Kayla F. Laserson Laurence Slutsker Walter Otieno Lucas Otieno Nekoye Otsyula Stacey Gondi Allan Otieno Victorine Owira Esther Oguk George S. Odongo Jon Ben Woods Bernhards Ogutu Patricia Njuguna Roma Chilengi Pauline Akoo Christine Kerubo Charity Maingi Trudie Lang Ally Olotu Philip Bejon Kevin Marsh Gabriel Mwambingu Seth Owusu‐Agyei Kwaku Poku Asante Kingsley Osei-Kwakye Owusu Boahen David Dosoo Isaac Asante George Adjei Evans Kwara Daniel Chandramohan Brian Greenwood John Lusingu Samwel Gesase Anangisye Malabeja Omari Abdul Msemo Coline Mahende Edwin Liheluka Lincoln Malle Martha Lemnge Thor G. Theander Chris Drakeley Daniel Ansong Tsiri Agbenyega Samuel Adjei Harry Owusu Boateng Theresa Rettig John Bawa Justice Sylverken David Sambian Anima Sarfo Alex Agyekum

The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe in children 5 to 17 months age by approximately 50% an ongoing phase 3 trial. We studied infants 6 12 weeks recruited for the same

10.1056/nejmoa1208394 article EN New England Journal of Medicine 2012-11-09
Didier Ménard Nimol Khim Johann Beghain Ayôla Akim Adégnika Mohammad Shafiul Alam and 84 more Olukemi K. Amodu Ghulam Rahim-Awab Céline Barnadas Antoine Berry Yap Boum Maria Dorina Bustos Jun Cao Jun-Hu Chen Louis Collet Liwang Cui Garib-Das Thakur Alioune Dièye Djibrine Djallé Améyo M. Dorkenoo Carole E. Eboumbou-Moukoko Fe-Esperanza-Caridad J. Espino Thierry Fandeur Maria-Fatima Ferreira-da-Cruz Abebe A. Fola Hans‐Peter Fuehrer Abdillahi Mohamed Hassan Sócrates Herrera Bouasy Hongvanthong Sandrine Houzé Maman Laminou Ibrahim Mohammad Jahirul-Karim Lubin Jiang Shigeyuki Kano Wasif Ali-Khan Maniphone Khanthavong Peter G. Kremsner Marcus Lacerda Rithea Leang Mindy Leelawong Li Mei Khin Lin Jean-Baptiste Mazarati Sandie Ménard Isabelle Morlais Hypolite Muhindo Mavoko L. Musset Kesara Na‐Bangchang Michael Nambozi Karamoko Niaré Harald Noedl Jean‐Bosco Ouédraogo Dylan R. Pillai Bruno Pradines Bui Quang-Phuc Michael Ramharter Milijaona Randrianarivelojosia Jetsumon Sattabongkot Abdiqani Sheikh-Omar Kigbafori D. Silué Sodiomon B. Sirima Colin J. Sutherland Din Syafruddin Rachida Tahar Lin-Hua Tang Offianan André Touré Patrick Tshibangu-wa-Tshibangu Inès Vigan-Womas Marian Warsame Lyndes Wini Sedigheh Zakeri Saorin Kim Rotha Eam Laura Berne Chanra Khean Sophy Chy Malen Ken Kaknika Loch Lydie Canier Valentine Duru Eric Legrand Jean-Christophe Barale Barbara H. Stokes Judith Straimer Benoît Witkowski David A. Fidock Christophe Rogier Pascal Ringwald Frédéric Ariey Odile Mercereau‐Puijalon

Recent gains in reducing the global burden of malaria are threatened by emergence Plasmodium falciparum resistance to artemisinins. The discovery that mutations portions a P. gene encoding kelch (K13)–propeller domains major determinant has provided opportunities for monitoring such on scale.

10.1056/nejmoa1513137 article EN New England Journal of Medicine 2016-06-23

The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.We performed three open-label, dose-escalation phase 1 trials one randomized, double-blind, controlled trial to assess the safety, side-effect profile, of rVSV-ZEBOV at various doses 158 healthy adults Europe Africa. All participants were injected with ranging from...

10.1056/nejmoa1502924 article EN New England Journal of Medicine 2015-04-02

The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical severe malaria disease in infants children. We investigated whether was specific to certain parasite genotypes at locus.We used polymerase chain reaction-based next-generation sequencing DNA extracted from samples 4985 participants survey polymorphisms. evaluated effect that polymorphic positions haplotypic regions within had on first episodes 1 year after...

10.1056/nejmoa1505819 article EN New England Journal of Medicine 2015-10-21

BackgroundThe RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with prevention of Plasmodium falciparum infection. We assessed association between anti-circumsporozoite antibody titres and magnitude duration efficacy using data from a phase 3 trial done 2009 2014.MethodsUsing 8922 African children aged 5–17 months 6537 infants 6–12 weeks at first vaccination, we analysed determinants immunogenicity after vaccination or without booster dose....

10.1016/s1473-3099(15)00239-x article EN cc-by The Lancet Infectious Diseases 2015-09-03

Background. Few studies have prospectively assessed viral etiologies of acute respiratory infections in community-based elderly individuals. We pathogens individuals ≥65 years with influenza-like illness (ILI). Methods. Multiplex reverse-transcriptase polymerase chain reaction identified nasal/throat swabs from 556 episodes moderate-to-severe ILI, defined as ILI pneumonia, hospitalization, or maximum daily influenza symptom severity score (ISS) >2. Cases were selected a randomized trial an...

10.1093/infdis/jit839 article EN The Journal of Infectious Diseases 2014-01-29

Artesunate is an antimalarial agent with broad anti-cancer activity in vitro and animal experiments case reports. has not been studied rigorous clinical trials for anticancer effects.To determine the effect tolerability of oral artesunate colorectal cancer (CRC).This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned curative resection biopsy confirmed primary site CRC were randomised (n = 23) by computer-generated code supplied opaque envelopes to...

10.1016/j.ebiom.2014.11.010 article EN cc-by EBioMedicine 2014-11-17
Peter G. Kremsner Rodolfo Andrés Ahuad Guerrero Eunate Arana‐Arri Gustavo Aroca Marc J. M. Bonten and 95 more Reynaldo Chandler Gonzalo Corral Eddie Jan Louis De Block Lucie Ecker Julian Gabor Carlos Alberto García López Lucy A. De Gonzales María Angélica Granados González Nestor Gorini Martin P. Grobusch Adrian D. Hrabar Helga Junker Alan Kimura Claudio F. Lanata Clara Lehmann Isabel Leroux‐Roels Philipp Mann Michel F. Martínez‐Reséndez Theresa J. Ochoa Carlos Poy María José Reyes Fentanes Luis Maria Rivera Mejia Vida Veronica Ruiz Herrera Xavier Sáez‐Llorens Oliver Schönborn‐Kellenberger Mirjam Schunk Alexandra Sierra Garcia Itziar Vergara Thomas Verstraeten Marisa Vico Lidia Oostvogels Luciano Lovesio Fabián Diez Franco Sebastián Grazziani María Cristina Ganaha Viviana Judith Zalatnik Ricardo Julio Dittrich Lidia Espínola Sandra Lambert Andrea Longhi Claudia Del Vecchio María Mastruzzo Alberto Ocaña Silvina Borchowiek Roberto Potito Rodolfo Andrés Ahuad Guerrero Fernando Martin Guardiani Sofia Castella Mónica Foccoli Aldana Pedernera Ariel Braida Virginia Durigan Carolina Martella Antonela Bobat Bruno Emilio Boggia Sergio Andrés Nemi Javier Gerardo Tartaglione Fabián Piedimonte Jessie De Bie Humberto Reynales Paula Andrea Rodríguez Ordóñez J M Cruz Leonardo Bautista Toloza M. Gonzalez Adriana Pilar Zambrano Ochoa Iñigo Prieto Pradera Daniela Torres-Hernández Diana Patricia Mazo Elorza Maria Fernanda Collazos Lennis Beatriz Vanegas Dominguez Lina Marianur Solano Mosquera Rolf Fendel Wim A. Fleischmann Erik Koehne Andrea Kreidenweiss Carsten Köhler Meral Esen Carola Horn Sandra M. Eberts Arne Kroidl Kristina Huber Verena Thiel Sonia Mazara Rosario G Uviedo Reyes Laura Rivera Yeycy Donastorg Flavia Lantigua Dania Torres Almanzar Rosalba Candelario Lourdes Peña Méndez Nadia Rosario Gomez Antonio Portolés Ana Ascaso Leonor Laredo Maria Jesus Bustinduy Odriozola

Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed analyse efficacy safety of CVnCoV SARS-CoV-2 mRNA vaccine candidate.HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres ten countries Europe Latin America. By use an interactive web response system stratification by country age group (18-60 years ≥61 years), adults with no history virologically confirmed were randomly assigned (1:1)...

10.1016/s1473-3099(21)00677-0 article EN other-oa The Lancet Infectious Diseases 2021-11-24

The gut microbiomes of human populations worldwide have many core microbial species in common. However, within a species, some strains can show remarkable population specificity. question is whether such specificity arises from shared evolutionary history (codiversification) between humans and their microbes. To test for codiversification host microbiota, we analyzed paired metagenomes genomes 1225 individuals Europe, Asia, Africa, including mothers children. Between countries, parallel was...

10.1126/science.abm7759 article EN Science 2022-09-15

We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP).This is an interim analysis dosage escalation phase 1 study healthy 18-60-year-old volunteers Hannover, Munich and Germany, Ghent, Belgium. After giving 2 intramuscular doses CVnCoV or placebo 28 days apart we assessed solicited local systemic...

10.1007/s00508-021-01922-y article EN cc-by Wiener klinische Wochenschrift 2021-08-10

Several studies have shown an inverse association between helminth infections and atopy, but none clearly established that the pathogens themselves, rather than other associated factors, cause suppression of atopy. To show a direct link, prospective intervention are required.A randomized, controlled trial was performed to study whether repeated anthelminthic treatment results in increased allergic sensitivity house dust mites (HDMs) chronically infected children. The population consisted 317...

10.1086/381767 article EN The Journal of Infectious Diseases 2004-02-23

Malaria parasites are sexually reproducing protozoa, although the extent of effective meiotic recombination in natural populations has been debated. If occurs frequently, compared with point mutation and mitotic rearrangement, linkage disequilibrium between polymorphic sites is expected to decline increasing distance along a chromosome. The rate this should be proportional population. Multiple covering 5-kb region chromosome 9 (the msp1 gene) have typed 547 isolates from six Africa test for...

10.1073/pnas.96.8.4506 article EN Proceedings of the National Academy of Sciences 1999-04-13

Rapid diagnosis and accurate quantification of Plasmodium falciparum parasitemia are important for the management malaria. The assessment disease severity also depends on evaluation metabolic indexes such as blood glucose lactate concentrations. Here we describe an rapid alternative to conventional thick film examination (Lambaréné method). We assess near-patient methods measuring (OneTouch) (Accusport). accuracy Lambaréné method is similar that thin films. Results from OneTouch meter in...

10.4269/ajtmh.2001.65.599 article EN American Journal of Tropical Medicine and Hygiene 2001-11-01

ABSTRACT We compared interleukin-12 (IL-12) and other cytokine activities during after an acute clinical episode in a matched-pair case-control study of young African children who presented with either mild or severe Plasmodium falciparum malaria. The acute-phase, pretreatment plasma IL-12 alpha interferon (IFN-α) levels, as well the acute-phase mitogen-stimulated whole-blood production capacity IL-12, were significantly lower rather than addition, showed strong inverse correlations both...

10.1128/iai.68.7.3909-3915.2000 article EN Infection and Immunity 2000-07-01

10.1016/s0140-6736(04)16680-4 article EN The Lancet 2004-07-01
Coming Soon ...